Skip to main content
European Commission logo print header

An Integral Platform for the Early Diagnosis of Skin Cancer

Project description

Cognitive computing system to detect melanoma

Skin cancer (melanoma) is one of the fastest rising forms of cancer. Discovered early, melanomas can be removed by surgery and patients have a very high chance of being cured. The EU-funded DermoSafe 2.0 project is developing an integral platform based on DermoBrain (a cognitive computing system) that enables the early detection of skin cancer for a broad population. The aim is to facilitate a fast professional analysis of potential skin lesion by employing dermoscopy imaging. It also reduces the lead time of the skin analysis results from 42 to 3 days. By further developing the DermoBrain system, the project will enable the recognition of skin lesion patterns as well as history tracking and evolution rating.


DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early
detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysis of
potential skin lesion by employing Dermoscopy Imaging. DermoSafe provides an accurate tool that allows patient performing
the needed increased analysis to combat the exploded incidence of skin cancer without the requirement of an appointment
with general practitioners or dermatologists, reducing lead time of the skin analysis results from 42 to 3 days. Hence, patient
uncertainty and anxiety is clearly diminished. Furthermore, DermoSafe enables a fast and easy access to Dermoscopy
experts to the healthcare professional community (pharmacies, general practitioners and dermatologists). DermoSafe has
demonstrated capability to overpass the limitations posed by current Dermoscopy devices for early and broad screening by
avoiding the need of a high investment to buy the equipment as well as offsets the lack of specialised dermatology
workforce. Once implemented in the healthcare system and at pharmacies, DermoSafe can reduce the skin cancer budget
up to 136,000€/patient. Since our platform and associated service will make the use of Dermoscopy imaging as broad as the
use of a thermometer, the business opportunity seems unquestionable. The objective of this project is the further
development of DermoBrain, to enable (1) skin lesion pattern recognition and identification for automatic history tracking and
evolution rating, (2) automatic image quality check, and (3) image automatic classification considering also the patient
medical context by artificial intelligence. By deploying DermoSafe platform in Europe, we aim to achieve a cumulative cash
flow of 10.7 M€ by 2024, resulting in a ROI of 4.2

Call for proposal


See other projects for this call

Sub call



DermoSafe SA
Net EU contribution
€ 50 000,00

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00